glp 1 analog Trends in the Development of GLP-1 Receptor Agonists Frontiers | Mechanisms of action

PMID: 37288303

Inflammatory bowel diseases (IBD), including Crohns disease (CD) and ulcerative colitis (UC), are chronic, relapsing, intestinal inflammatory disorders with complex and yet unrevealed pathogenesis in which genetic, immunological, and environmental factors play a role

The Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market worth USD 2.91 billion in 2026 is growing at a CAGR of 8.24% to reach USD 4.33 billion by 2031

I recently received an email promoting GLP-1 support protocols

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a class of agents that have evolved rapidly in recent years